Publications: DR Upkar Gill

Picchio CA, Nicolàs A, Duffell E, Martró E, Vickerman P, Dudareva S, Lens S, Vanderlinden A et al. ( 2026 ) . From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe . The Lancet Regional Health - Europe vol. 65 ,

D'Anna S, Piermatteo L, Grossi I, Brancaccio G, Carioti L, Di Lorenzo A, Poldiallai T, Pasqualini L et al. ( 2026 ) . OS-076-YI Long-read sequencing unveils extensive HBV-DNA integration driving massive HBsAg production and sustaining HDV persistence . Journal of Hepatology vol. 84 , s49 - s50 .

Mohamed A, Watson A, Lucas S, Jones A, Jeffery-Smith A, Riddell A, Koffas A, Gill U et al. ( 2026 ) . SAT-611 Integrating double reflex hepatitis D virus testing to reduce diagnostic gaps and streamline clinical pathways . Journal of Hepatology vol. 84 ,

Mak LYL, Pade C, Xiong S, Fernandes C, Lei Y, Hernandez-Mir G, Riddell A, Koffas A et al. ( 2026 ) . THU-575 Immunometabolic stress drives persistent bystander activation of innate-like CD8+ T cells and hepatocyte HBV transcription despite antiviral therapy . Journal of Hepatology vol. 84 ,

Parisi E, Fernandes C, Arora J, Pade C, Koffas A, Kennedy P, Gill U ( 2026 ) . THU-618 Distinct hepatic transcriptional programmes in chronic hepatitis B are reshaped by metabolic dysfunction . Journal of Hepatology vol. 84 , s888 - s889 .

Mulay A, Cai J, Arora J, Hernandez-Mir G, Kennedy P, Gill U ( 2026 ) . WED-347 Lessons from single-cell transcriptomics in chronic hepatitis B: refinement without redefinition . Journal of Hepatology vol. 84 , s370 - s371 .

Boonstra A, Gehring A, Ghosheh Y, Alatrakchi N, Gill US, Beudeker B, Chung RT, Feld J et al. ( 2026 ) . Intrahepatic and peripheral immunophenotyping of participants with chronic hepatitis B receiving bepirovirsen in the B-Fine study strongly suggests that bepirovirsen may trigger a humoral response . Zeitschrift für Gastroenterologie . Conference: 42. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber vol. 64 , e52 - e52 .

Constantinides M, Gafton J, Garcia ACA, Dixon PH, Williamson C, Linton K, Finer S, Gill US et al. ( 2025 ) . A genes and health recall study of intrahepatic cholestasis of pregnancy and cholestatic liver disease . Communications Medicine vol. 5 , ( 1 )

Preechanukul A, Alrubayyi A, Sun B, Arbe-Barnes E, Kokici J, Gorou F, Prasitdumrong S, da Costa KAS et al. ( 2025 ) . Stem-like CD8+ T cells preserve HBV-specific responses in HBV/HIV co-infection . Gut vol. 75 , ( 7 ) 1397 - 1410 .

Watson AG, Mulay AS, Gill US ( 2025 ) . Chronic hepatitis B in 2025: diagnosis, treatment and future directions . Clinical Medicine vol. 25 , ( 6 )

Kokiçi J, Arellano-Ballestero H, Hammond B, Preechanukul A, Hussain N, da Costa K, Davies J, Mukhtar S et al. ( 2025 ) . Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell lines . Cytotherapy vol. 28 , ( 3 )

Aidoo-Micah G, Kucykowicz S, Schmidt N, Naidu V, Shah R, Khara S, Mckinnon-Snell T, Zhong Y et al. ( 2025 ) . Fine needle aspirates characterise the hepatocellular carcinoma immune niche to predict immune checkpoint inhibitor outcomes . JHEP Reports vol. 8 , ( 1 )

Mak LL-Y, Xiong S, Deschler S, Pade C, Fernandes C, Miao T, Lei Y, Hernandez-Mir G et al. ( 2025 ) . P159 Innate-like CD56 + CD8 + T cells exhibit bystander function and metabolic sensitivity in chronic hepatitis B . Conference: P159 Innate-like CD56+ CD8+ T cells exhibit bystander function and metabolic sensitivity in chronic hepatitis Ba117.2 - a1a118 .

Jones A, Moothathamby T, Gupta P, Gill U, Koffas A ( 2025 ) . P162 Follow-up of patients with hepatitis C who achieved sustained virological response: a pharmacist-led service evaluation . Conference: P162 Follow-up of patients with hepatitis C who achieved sustained virological response: a pharmacist-led service evaluationa119.1 - a1a119 .

Gill US, Appleby VJ, Lens S ( 2025 ) . ‘What is new in hepatitis B’ . Frontline Gastroenterology vol. 17 , ( 2 ) 161 - 171 .

Fink DL, Etoori D, Hill R, Idilli O, Kartikapallil N, Payne O, Griffith S, Bradford HF et al. ( 2025 ) . Corrigendum to “Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFNα non-response” [J Hepatol (2025) 101382] . JHEP Reports vol. 7 , ( 10 )

Le Bert N, Koffas A, Kumar R, Facchetti F, Tan AT, Gill US, Mak L-Y, Stretch SW et al. ( 2025 ) . Rapid whole-blood immune profiling reveals heterogeneous HBV-specific T cell response patterns independent of clinical disease phases . Journal of Hepatology vol. 83 , ( 6 ) 1292 - 1304 .

Mak L-Y, Gill U, Yang L, Seto W-K, Kennedy P, Yuen M-F ( 2025 ) . Mitigation of Immune Dysfunction in Patients with Sustained Suppression of Hepatitis B Surface Antigen After siRNA Treatment . EMJ Hepatology vol. 13 , ( 1 ) 42 - 43 .

Aidoo-Micah G, Kucykowicz S, Naidu V, Khara S, McKinnon-Snell T, Shah R, Romero DB, Zhong Y et al. ( 2025 ) . FRI-046-YI Fine needle aspiration reveals immunotherapy biomarkers and targets compartmentalised within hepatocellular carcinoma . Journal of Hepatology vol. 82 , s358 - s359 .

Mak LYL, Xiong S, Miao T, Hernandez-Mir G, Lei Y, Riddell A, Koffas A, Kennedy P et al. ( 2025 ) . FRI-261 Persistent immune defects in innate-like CD8 T cells despite antiviral therapy in chronic hepatitis B . Journal of Hepatology vol. 82 ,

Mak LYL, Gill U, Yang L, Seto W-K, Kennedy P, Yuen M-F ( 2025 ) . OS-071 Mitigation of immune dysfunction in patients with sustained suppression of hepatitis B surface antigen after siRNA treatment . Journal of Hepatology vol. 82 , s51 - s52 .

D’Anna S, Piermatteo L, Di Lorenzo A, Carioti L, Brancaccio G, Teti E, Grossi I, Torre G et al. ( 2025 ) . OS-072-YI HBV integration can sustain HDV persistence especially in the setting of an absent HBV reservoir and can be a biomarker of response to bulevirtide . Journal of Hepatology vol. 82 ,

Sandwith P, Agarwal K, Foster GR, Emmanouil B, Gillyon-Powell M, Nabiteeko S, Threadgold G, Surey J et al. ( 2025 ) . SAT-021 Initiation of direct acting viral therapy in prison is associated with a significant loss to follow-up: relevance to WHO elimination metrics? . Journal of Hepatology vol. 82 , s704 - s705 .

Sandwith P, Agarwal K, Foster GR, Emmanouil B, Gillyon-Powell M, Nabiteeko S, Threadgold G, Surey J et al. ( 2025 ) . SAT-023 Treatment of Hepatitis C in the over-80 s in the direct anti-viral therapy era: age is no barrier! . Journal of Hepatology vol. 82 , s705 - s706 .

Chalatsis E, Koffas A, Mohamed A, Riddell A, Gill U, Kennedy P ( 2025 ) . SAT-259 Long-term outcomes of 'Grey Zone’ (GZ) individuals living with HBeAg-negative chronic hepatitis B in a tertiary UK centre . Journal of Hepatology vol. 82 ,

Gupta P, Moothathamby T, Gill U, Koffas A, Jones A ( 2025 ) . THU-207-YI Clinical follow up in patients treated for hepatitis C . Journal of Hepatology vol. 82 ,

Hill-Tout R, Foster GR, Brown A, Macdonald D, Forton D, Kennedy P, Foxton M, Trembling P et al. ( 2025 ) . TOP-015 Emergency department opt out testing for HBV and HCV in London with integrated linkage to care: an effective initiative to diagnose hepatitis or work in progress? . Journal of Hepatology vol. 82 ,

Sandwith P, Foxton M, Foster GR, Emmanouil B, Gillyon-Powell M, Nabiteeko S, Threadgold G, Surey J et al. ( 2025 ) . WED-275 Retreatment of HCV in a large metropolis – implications for WHO elimination targets? The London experience . Journal of Hepatology vol. 82 , s855 - s856 .

Fink DL, Etoori D, Hill R, Idilli O, Kartikapallil N, Payne O, Griffith S, Bradford HF et al. ( 2025 ) . Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFNα non-response . JHEP Reports vol. 7 , ( 5 )

D'Anna S, Piermatteo L, Brancaccio G, Teti E, Di Lorenzo A, Grossi I, Torre G, Malagnino V et al. ( 2025 ) . HDV persistence acts independently from HBV reservoir extent and is sustained by HBsAg production mainly derived from integrated HBV-DNA . Digestive and Liver Disease vol. 57 ,

Mak L-Y, Boettler T, Gill US ( 2024 ) . HBV Biomarkers and Their Role in Guiding Treatment Decisions . Seminars in Liver Disease vol. 44 , ( 04 ) 474 - 491 .

Aidoo-Micah GE, Kucykowicz S, Naidu V, Romero DB, Shah R, Schmidt N, McKinnon-Snell T, Zhong Y et al. ( 2024 ) . 224 Probing tumor immune evasion via local immune profiling with fine needle aspirates in hepatocellular carcinoma . Conference: Regular and Young Investigator Award Abstractsa256 - a256 .

Ngan T, Li W, Cai J, Barker G, Naik S, Koffas A, Riddell A, Kennedy PT et al. ( 2024 ) . P133 The impact of viral genotype in the kinetics hepatitis B surface antigen decline during antiviral therapy, in an East London cohort of chronic hepatitis B patients . Conference: P133 The impact of viral genotype in the kinetics hepatitis B surface antigen decline during antiviral therapy, in an East London cohort of chronic hepatitis B patientsa94.2 - a9a94 .

Cross A, Harris JM, Arbe-Barnes E, Nixon C, Dhairyawan R, Hall A, Quaglia A, Issa F et al. ( 2024 ) . Characterisation of HBV and co-infection with HDV and HIV through spatial transcriptomics . eGastroenterology vol. 2 , ( 3 )

Mak LYL, Koffas A, Dolman G, Lei Y, Riddell A, Gill U, Kennedy P ( 2024 ) . FRI-413 Prevalence, fate and implication of gray zone on the trajectory of hepatitis B surface antigen in treatment-naïve young adults with chronic hepatitis B infection . Journal of Hepatology vol. 80 ,

Salpini R, D'Anna S, Piermatteo L, Brancaccio G, Teti E, Di Lorenzo A, Grossi I, Torre G et al. ( 2024 ) . OS-094 Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBV-DNA in the setting of a limited or even absent HBV reservoir . Journal of Hepatology vol. 80 , s59 - s60 .

Le Bert N, Koffas A, Tan A, Kumar R, Mak L-Y, Miao T, Lei Y, Hariharaputran S et al. ( 2024 ) . SAT-383 Rapid analysis of HBV-specific T cell secretomes reveals distinct antiviral immune profiles among chronic HBV patients . Journal of Hepatology vol. 80 , s742 - s743 .

Sun B, da Costa KAS, Alrubayyi A, Kokici J, Fisher-Pearson N, Hussain N, D’Anna S, Piermatteo L et al. ( 2024 ) . HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responses . Hepatology vol. 80 , ( 3 ) 649 - 663 .

Moreno-Cubero E, Alrubayyi A, Balint S, Ogbe A, Gill US, Matthews R, Kinloch S, Burns F et al. ( 2024 ) . IL-15 reprogramming compensates for NK cell mitochondrial dysfunction in HIV-1 infection . JCI Insight vol. 9 , ( 4 )

Zeng G, Holmes BR, Alqahtani SA, Gill US, Kennedy PTF ( 2024 ) . The co-existence of NAFLD and CHB is associated with suboptimal viral and biochemical response to CHB antiviral therapy: a systematic review and meta-analysis . Frontiers in Gastroenterology vol. 3 ,

Mak L, Koffas A, Dolman GE, Saleh H, Kemos P, Riddell A, Gill U, Kennedy PTF ( 2023 ) . Role of HBsAg levels in guiding hepatitis B virus prophylaxis in pregnancy: Insights from a multi‐ethnic cohort . Journal of Viral Hepatitis vol. 31 , ( 1 ) 3 - 11 .

Gill US, Peppa D ( 2023 ) . Pegylated interferon-α for chronic hepatitis B … not ready to be shelved yet! New insights on its role using single-cell transcriptomics . Hepatology vol. 79 , ( 1 ) 18 - 20 .

Testoni B, Suarez AAR, Battisti A, Plissonnier M-L, Heil M, Fontanges T, Villeret F, Chouik Y et al. ( 2023 ) . Evaluation of the HBV liver reservoir with fine needle aspirates . JHEP Reports vol. 5 , ( 10 )

Le Bert N, Koffas A, Tan A, Mak L-Y, Stretch S, Hang SK, Ma H, Lee A et al. ( 2023 ) . FRI-229 Rapid functional secretome analysis of HBV-specific T cells to guide clinical management of CHB patients . Journal of Hepatology vol. 78 , s1024 - s1025 .

Mak LYL, Koffas A, Wellington S, Stretch S, Riddell A, Yuen M-F, Kennedy P, Gill U ( 2023 ) . FRI-246 Nucleotide analogue therapy does not reverse the hyperexpression of innate-like markers on activated T cells consistent with immunopathology in chronic hepatitis B . Journal of Hepatology vol. 78 ,

Testoni B, Suarez AAR, Battisti A, Plissonnier M-L, Heil M, Fontanges T, Villeret F, Chouik Y et al. ( 2023 ) . LBP-27 Evaluation of the hepatitis B virus liver reservoir with fine needle aspirates . Journal of Hepatology vol. 78 , s118 - s119 .

Aidoo-Micah G, Kucykowicz S, Schmidt N, Trinh A, Pallett LJ, Romero DB, Naidu V, Shah R et al. ( 2023 ) . SAT-271 Monitoring the local HCC immune landscape by fine needle aspiration . Journal of Hepatology vol. 78 , s558 - s559 .

Salpini R, Piermatteo L, D’Anna S, Duca L, Torre G, Guerra AF, Boarini C, Tavelli A et al. ( 2023 ) . WED-176 Ultrasensitive HBV-RNA quantification by droplet digital PCR is a promising biomarker to optimize the staging of chronic HBV infection and to identify minimal viral activity under prolonged virological suppression . Journal of Hepatology vol. 78 ,

Koffas A, Gill US ( 2023 ) . Hepatitis B and D: an overview of the diagnosis and management . Medicine vol. 51 , ( 5 ) 351 - 355 .

Zeng G, Koffas A, Mak L-Y, Gill US, Kennedy PTF ( 2023 ) . Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies . JHEP Reports vol. 5 , ( 6 )

Knight CH, Khan F, Patel A, Gill US, Okosun J, Wang J ( 2023 ) . IBRAP: integrated benchmarking single-cell RNA-sequencing analytical pipeline . Briefings in Bioinformatics vol. 24 , ( 2 )

Pallett LJ, Swadling L, Diniz M, Maini AA, Schwabenland M, Gasull AD, Davies J, Kucykowicz S et al. ( 2023 ) . Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS . Nature vol. 614 , ( 7947 ) 334 - 342 .

Gill US ( 2023 ) . The immune landscape in hepatitis delta virus infection—Still an open field . Journal of Viral Hepatitis vol. 30 , ( S1 ) 22 - 26 .

Testoni B, Suarez AAR, Battisti A, Plissonnier M-L, Heil M, Fontanges T, Villeret F, Chouik Y et al. ( 2023 ) . Evaluation of the hepatitis B virus liver reservoir with fine needle aspirates . JOURNAL OF HEPATOLOGY . vol. 78 , S118 - S119 .

Aidoo-Micah G, Kucykowicz S, Schmidt N, Trinh A, Pallett LJ, Romero DB, Naidu V, Shah R et al. ( 2023 ) . Monitoring the local HCC immune landscape by fine needle aspiration . JOURNAL OF HEPATOLOGY . vol. 78 , S558 - S559 .

Mak LYL, Koffas A, Wellington S, Stretch S, Riddell A, Yuen M-F, Kennedy P, Gill U ( 2023 ) . Nucleotide analogue therapy does not reverse the hyperexpression of innate-like markers on activated T cells consistent with immunopathology in chronic hepatitis B . JOURNAL OF HEPATOLOGY . vol. 78 , S1033 - S1033 .

Le Bert N, Koffas A, Tan A, Mak L-Y, Stretch S, Hang SK, Ma H, Lee A et al. ( 2023 ) . Rapid functional secretome analysis of HBV-specific T cells to guide clinical management of CHB patients . JOURNAL OF HEPATOLOGY . vol. 78 , S1024 - S1025 .

Salpini R, Piermatteo L, D'Anna S, Duca L, Torre G, Guerra AF, Boarini C, Tavelli A et al. ( 2023 ) . Ultrasensitive HBV-RNA quantification by droplet digital PCR is a promising biomarker to optimize the staging of chronic HBV infection and to identify minimal viral activity under prolonged virological suppression . JOURNAL OF HEPATOLOGY . vol. 78 , S1105 - S1105 .

Hansi N, Mak LL-Y, Gill U, Kennedy P ( 2022 ) . Chronic Hepatitis B . Liver Disease in Clinical Practice , Springer Nature

Loey Mak LY, Koffas A, Dolman G, Saleh H, Kemos P, Riddell A, Gill U, Kennedy P ( 2022 ) . P75 Inter-ethnic differences of quantitative hepatitis B surface antigen (qHBsAg) in predicting highly viraemic pregnancy with chronic hepatitis B infection . Conference: Abstractsa87 - a89 .

Salpini R, D’Anna S, Benedetti L, Piermatteo L, Gill U, Svicher V, Kennedy PTF ( 2022 ) . Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure . Frontiers in Microbiology vol. 13 ,

Pallett LJ, Diniz M, Swadling L, Skelton J, Maini A, Davies J, Kucykowicz S, Schmidt N et al. ( 2022 ) . OS070 CD8+ T cell acquisition of the LPS receptor within the hepatic stroma shapes anti-viral/anti-tumour potential . Journal of Hepatology vol. 77 , s55 - s56 .

Salpini R, Carioti L, Battisti A, Piermatteo L, Benedetti L, Silberstein FC, Gill U, Svicher V et al. ( 2022 ) . THU380 Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the setting of HBeAg positive infection . Journal of Hepatology vol. 77 ,

Koffas A, Mak L-Y, Gill US, Kennedy PTF ( 2022 ) . Early Treatment Consideration in Patients with Hepatitis B ‘e’ Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift? . Viruses vol. 14 , ( 5 )

Boettler T, Gill US, Allweiss L, Pollicino T, Tavis JE, Zoulim F ( 2022 ) . Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection . JHEP Reports vol. 4 , ( 6 )

Usai C, Gill US, Riddell AC, Asselah T, Kennedy PT ( 2022 ) . Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus . Alimentary Pharmacology & Therapeutics vol. 55 , ( 8 ) 978 - 993 .

Zaki MYW, Fathi AM, Samir S, Eldafashi N, William KY, Nazmy MH, Fathy M, Gill US et al. ( 2022 ) . Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma . Cancers vol. 14 , ( 5 )

Khoo NKH, Lim JME, Gill US, de Alwis R, Tan N, Toh JZN, Abbott JE, Usai C et al. ( 2022 ) . Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients . Med vol. 3 , ( 2 ) 104 - 118.e4 .

Gill US, Lemoine M ( 2022 ) . Making safe sense of an anti-sense! . Cell Reports Medicine vol. 3 , ( 1 )

Usai C, Gibbons JM, Pade C, Li W, Jacobs SRM, McKnight Á, Kennedy PTF, Gill US ( 2022 ) . The β-NGF/TrkA Signalling Pathway Is Associated With the Production of Anti-Nucleoprotein IgG in Convalescent COVID-19 . Frontiers in Immunology vol. 12 ,

Pallett LJ, Diniz M, Swadling L, Skelton J, Maini A, Davies J, Kucykowicz S, Schmidt N et al. ( 2022 ) . CD8+T cell acquisition of the LPS receptor within the hepatic stroma shapes anti-viral/anti-tumour potential . JOURNAL OF HEPATOLOGY . vol. 77 , S55 - S56 .

Salpini R, Carioti L, Battisti A, Piermatteo L, Benedetti L, Silberstein FC, Gill U, Svicher V et al. ( 2022 ) . Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the setting of HBeAg positive infection . JOURNAL OF HEPATOLOGY . vol. 77 , S284 - S284 .

Piermatteo L, Alkhatib M, D’Anna S, Malagnino V, Bertoli A, Andreassi E, Basile E, Iuvara A et al. ( 2021 ) . HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation . Biomedicines vol. 9 , ( 10 )

Wiggins BG, Pallett LJ, Li X, Davies SP, Amin OE, Gill US, Kucykowicz S, Patel AM et al. ( 2021 ) . The human liver microenvironment shapes the homing and function of CD4+ T-cell populations . Gut vol. 71 , ( 7 ) 1399 - 1411 .

Tavabie OD, Abeysekera KWM, Gill US ( 2021 ) . We need to talk about #livertwitter . Journal of Hepatology vol. 75 , ( 5 ) 1239 - 1240 .

Choudhry N, Drysdale K, Usai C, Leighton D, Sonagara V, Buchanan R, Nijjar M, Thomas S et al. ( 2021 ) . Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK . Frontiers in Medicine vol. 8 ,

Koffas A, Kumar M, Gill US, Jindal A, Kennedy PTF, Sarin SK ( 2021 ) . Chronic hepatitis B: the demise of the ‘inactive carrier’ phase . Hepatology International vol. 15 , ( 2 ) 290 - 300 .

Svicher V, Salpini R, Piermatteo L, Carioti L, Battisti A, Colagrossi L, Scutari R, Surdo M et al. ( 2020 ) . Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B . Gut vol. 70 , ( 12 ) 2337 - 2348 .

Tavabie O, Clough J, Blackwell J, Bashyam M, Martin H, Soubieres A, Direkze N, Graham D et al. ( 2020 ) . IDDF2020-ABS-0163 Reduced survival post-endoscopy for upper gastrointestinal bleeding in the COVID-19 era is a secondary effect of the response to the global pandemic . Gut . Conference: Abstracts vol. 69 , a55 - a56 .

Tavabie OD, Clough JN, Blackwell J, Bashyam M, Martin H, Soubieres A, Direkze N, Graham D et al. ( 2020 ) . Reduced survival after upper gastrointestinal bleed endoscopy in the COVID-19 era is a secondary effect of the response to the global pandemic: a retrospective cohort study . Frontline Gastroenterology vol. 12 , ( 4 ) 279 - 287 .

Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, Brenner EJ et al. ( 2020 ) . Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study . Journal of Hepatology vol. 74 , ( 3 ) 567 - 577 .

Phillips S, Mistry S, Coombes J, Hadzhiolova T, Doornebal E, Harris N, Palma E, Riva A et al. ( 2020 ) . SAT384 Osteopontin drives HBV replication and HBV-driven fibrogenesis and represents a novel therapeutic target to achieve functional cure in chronic hepatitis B . Journal of Hepatology vol. 73 ,

Zeng G, Gill US, Kennedy PTF ( 2020 ) . Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis . Gut vol. 69 , ( 11 ) 1907 - 1912 .

Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genescà J, Gill US et al. ( 2020 ) . High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry . Journal of Hepatology vol. 73 , ( 3 ) 705 - 708 .

Salpini R, Battisti A, Piermatteo L, Carioti L, Anastasiou OE, Gill US, Di Carlo D, Colagrossi L et al. ( 2020 ) . Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection . Emerging Microbes & Infections vol. 9 , ( 1 ) 928 - 939 .

Le Bert N, Gill US, Hong M, Kunasegaran K, Tan DZM, Ahmad R, Cheng Y, Dutertre C-A et al. ( 2020 ) . Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection . Gastroenterology vol. 159 , ( 2 ) 652 - 664 .

Bigogno CM, Falahieh RR, Ho KMA, Jeffrey-Smith A, Jones M, Usai C, Battisti A, Gill U et al. ( 2020 ) . The genetic landscape of hepatitis delta virus infection . Clinical Medicine vol. 20 , ( Suppl 2 )

Bertoletti A, Gill US, Kennedy PTF ( 2020 ) . Early treatment of chronic hepatitis B in children: Everything to play for? . Journal of Hepatology vol. 72 , ( 4 ) 802 - 803 .

Phillips S, Mistry S, Coombes J, Hadzhiolova T, Doornebal E, Harris N, Palma E, Riva A et al. ( 2020 ) . Osteopontin drives HBV replication and HBV-driven fibrogenesis and represents a novel therapeutic target to achieve functional cure in chronic hepatitis B . JOURNAL OF HEPATOLOGY . vol. 73 , S845 - S845 .

Tavabie O, Clough JN, Blackwell J, Bashyam M, Martin H, Soubieres A, Direkze N, Graham D et al. ( 2020 ) . Reduced Survival After Gastrointestinal Bleed Endoscopy in the COVID-19 Era Is a Secondary Effect of the Global Pandemic: A Retrospective Cohort Study .

Gill US, Battisti A, Kennedy PTF ( 2019 ) . Emerging tools in the changing landscape of chronic hepatitis B management . Expert Review of Anti-infective Therapy vol. 17 , ( 12 ) 943 - 955 .

Gill US, McCarthy NE ( 2019 ) . CD4 T cells in hepatitis B virus: “You don’t have to be cytotoxic to work here and help” . Journal of Hepatology vol. 72 , ( 1 ) 9 - 11 .

Le Bert N, Salimzadeh L, Gill US, Dutertre C-A, Facchetti F, Tan A, Hung M, Novikov N et al. ( 2019 ) . Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B . Journal of Hepatology vol. 72 , ( 1 ) 34 - 44 .

Svicher V, Salpini R, Battisti A, Colagrossi L, Piermatteo L, Surdo M, Cacciafesta V, Nuccitelli A et al. ( 2019 ) . GS-17-The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative disease: Implications for the treatment and management of CHB . Journal of Hepatology . vol. 70 , e83 - e84 .

Piermatteo L, Battisti A, Carioti L, Anastasiou O, Gill US, Colagrossi L, Bertoli A, Aragri M et al. ( 2019 ) . SAT-190-Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels in vivo, hamper HBsAg secretion in vitro and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection . Journal of Hepatology vol. 70 , ( 1 )

Koffas A, Gill U, Kennedy P ( 2019 ) . Hepatitis B: Prognosis and Treatment . Evidence‐based Gastroenterology and Hepatology 4e , Wiley

Piermatteo L, Battisti A, Carioti L, Anastasiou O, Gill US, Colagrossi L, Bertoli A, Aragri M et al. ( 2019 ) . Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection . Digestive and Liver Disease . vol. 51 ,

Salpini R, Carioti L, Battisti A, Colagrossi L, Piermatteo L, Surdo M, Cacciafesta V, Nuccitelli A et al. ( 2019 ) . The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative chronic infection: implications for an altered cell homeostasis and metabolism . Digestive and Liver Disease . vol. 51 ,

Gill US, Le Bert N, Kunasegaran K, Hansi N, Tan D, Peppa D, Maini MK, Bertoletti A et al. ( 2019 ) . GENE ONTOLOGY ENRICHMENT AND INGENUITY PATHWAY ANALYSIS REVEALS DIFFERENTIALLY IMMUNE REGULATED NETWORKS IN TREATED COMPARED TO UNTREATED CHRONIC HEPATITIS B PATIENTS . HEPATOLOGY . vol. 70 , 609A - 609A .

Piermatteo L, Battisti A, Carioti L, Anastasiou O, Gill US, Colagrossi L, Bertoli A, Aragri M et al. ( 2019 ) . Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels in vivo, hamper HBsAg secretion in vitro and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection . JOURNAL OF HEPATOLOGY . vol. 70 , E713 - E714 .

Gill US, Golden-Mason L ( 2018 ) . HCMV jogs the ‘memory’ of NK cells in HBV . Journal of Hepatology vol. 70 , ( 3 ) 343 - 345 .

Gill US, Kennedy PTF ( 2018 ) . The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics . Journal of Viral Hepatitis vol. 26 , ( 1 ) 4 - 15 .

Gill US, Pallett LJ, Thomas N, Burton AR, Patel AA, Yona S, Kennedy PTF, Maini MK ( 2018 ) . Fine needle aspirates comprehensively sample intrahepatic immunity . Gut vol. 68 , ( 8 ) 1493 - 1503 .

Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR et al. ( 2018 ) . Circulating and intrahepatic antiviral B cells are defective in hepatitis B . Journal of Clinical Investigation vol. 128 , ( 10 ) 4588 - 4603 .

Salimzadeh L, Le Bert N, Dutertre C-A, Gill US, Newell EW, Frey C, Hung M, Novikov N et al. ( 2018 ) . PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection . Journal of Clinical Investigation vol. 128 , ( 10 ) 4573 - 4587 .

Svicher V, Salpini R, Colagrossi L, Carlo DD, Battisti A, Piermatteo L, Hansi N, Silberstein FC et al. ( 2018 ) . FRI-272 Combination of HBV serological markers to predict the burden and productivity of intrahepatic HBV reservoir and disease progression in HBeAg negative Chronic Hepatitis B . Journal of Hepatology . vol. 68 ,

Colagrossi L, Salpini R, Gill US, Battisti A, Piermatteo L, Carlo DD, Hansi N, Silberstein FC et al. ( 2018 ) . FRI-277 Basal core promoter mutations as potential predictors of an enlarged intrahepatic HBV reservoir and enhanced cccDNA transcriptional activity in HBeAg negative chronic hepatitis B infection . Journal of Hepatology . vol. 68 ,

Salpini R, Battisti A, Carioti L, Carlo DD, Anastasiou O, Gill US, Colagrossi L, Bertoli A et al. ( 2018 ) . FRI-293 Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection . Journal of Hepatology . vol. 68 , s492 - s493 .

Salimzadeh L, Le Bert N, Gill US, Kennedy P, Samuel D, Novikov N, Frey C, Fletcher S et al. ( 2018 ) . PS-114 Exhaustion of virus-specific and total B cellpopulations by HBV infection . Journal of Hepatology . vol. 68 ,

Phillips S, Coombes J, Mistry S, Simonova M, Hadzhiolova T, Pavlova S, Katzarov K, Kennedy P et al. ( 2018 ) . SAT-378 Pro-fibrogenic mediator osteopontin is intimately involved in chronic hepatitis B and promotes cccDNA production . Journal of Hepatology . vol. 68 ,

Burton A, Pallett LJ, Mccoy L, Suveizdyte K, Amin OE, Froghi F, Davidson BR, Gill US et al. ( 2018 ) . SAT-413 Dysfunctional surface antigen-specific memory B cells accumulate in chronic hepatitis B infection . Journal of Hepatology . vol. 68 , s792 - s793 .

Gill US, Pallett LJ, Burton A, Stegmann K, Kennedy P, Maini M ( 2018 ) . SAT-415 Probing new HBV therapies using fine needle aspirates to sample compartmentalised liver-resident immunity and hepatocytes . Journal of Hepatology vol. 68 ,

Gill US, Hansi N, Bert NL, Kunasegaran K, Dolman GE, Tan D, Tong W, Maini M et al. ( 2018 ) . SAT-416 HBV-specific T cell responses in low replicating inactive carrier patients are independent of Hepatitis B surface antigen load . Journal of Hepatology vol. 68 , s793 - s794 .

Bert NL, Hong M, Tan D, Kunasegaran K, Cheng Y, Brecht E, Gill US, Frey C et al. ( 2018 ) . SAT-419 The impact of HBsAg on general and HBV-specific immunity . Journal of Hepatology . vol. 68 ,

Salpini R, Colagrossi L, Gill US, Battisti A, Piermatteo L, Hansi N, Perno CF, Kennedy PTF et al. ( 2018 ) . Combination of HBV serological markers can predict the burden and productivity of intrahepatic HBV reservoir and disease progression in HBeAg-negative chronic hepatitis B infection . Digestive and Liver Disease . vol. 50 ,

Colagrossi L, Salpini R, Gill US, Battisti A, Piermatteo L, Di Carlo D, Hansi N, Ceccherini-Silberstein F et al. ( 2018 ) . HBV reservoir and enhanced cccDNA transcriptional activity in HBeAg negative chronic hepatitis B . Digestive and Liver Disease . vol. 50 ,

Gill US, Pallett LJ, Kennedy PTF, Maini MK ( 2018 ) . Liver sampling: a vital window into HBV pathogenesis on the path to functional cure . Gut vol. 67 , ( 4 )

Rivino L, Le Bert N, Gill US, Kunasegaran K, Cheng Y, Tan DZM, Becht E, Hansi NK et al. ( 2018 ) . Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation . Journal of Clinical Investigation vol. 128 , ( 2 ) 668 - 681 .

Salimzadeh L, Le Bert N, Gill US, Kennedy PT, Samuel D, Novikov N, Frey CR, Fletcher S et al. ( 2018 ) . Dysfunctional HBsAg-specific and modified global B cells in chronic Hepatitis B virus infection . JOURNAL OF VIRAL HEPATITIS . vol. 25 , 34 - 35 .

Gill US, Hansi N, Bert NL, Kunasegaran K, Dolman GE, Tan D, Tong W, Maini M et al. ( 2018 ) . HBV-specific T cell responses in low replicating inactive carrier patients are independent of Hepatitis B surface antigen load . JOURNAL OF HEPATOLOGY . vol. 68 , S793 - S794 .

Gill US, Pallett LJ, Thomas N, Burton AR, Stegmann KA, Kennedy PTF, Maini MK ( 2018 ) . Probing Novel HBV Therapies Using Fine Needle Aspirates to Sample Compartmentalised Liver-Resident Immunity and Hepatocytes . HEPATOLOGY . vol. 68 , 152A - 152A .

Gill US, Pallett LJ, Burton A, Stegmann K, Kennedy P, Maini M ( 2018 ) . Probing new HBV therapies using fine needle aspirates to sample compartmentalised liver-resident immunity and hepatocytes . JOURNAL OF HEPATOLOGY . vol. 68 , S793 - S793 .

Le Bert N, Hong M, Tan D, Kunasegaran K, Cheng Y, Brecht E, Gill U, Frey C et al. ( 2018 ) . The impact of HBsAg on general and HBV-specific immunity . JOURNAL OF VIRAL HEPATITIS . vol. 25 , 35 - 35 .

Singh HD, Otano I, Rombouts K, Singh KP, Peppa D, Gill US, Böttcher K, Kennedy PTF et al. ( 2017 ) . TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis . Scientific Reports vol. 7 , ( 1 )

Gill US, Kennedy PTF ( 2017 ) . Current therapeutic approaches for HBV infected patients . Journal of Hepatology vol. 67 , ( 2 ) 412 - 414 .

Duriez M, Mandouri Y, Lekbaby B, Wang H, Schnuriger A, Redelsperger F, Guerrera CI, Lefevre M et al. ( 2017 ) . Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity . Journal of Hepatology vol. 67 , ( 4 ) 687 - 699 .

Gill U, Bertoletti A ( 2017 ) . Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus . Seminars in Liver Disease vol. 37 , ( 02 ) 085 - 094 .

Pallett LJ, Davies J, Colbeck EJ, Robertson F, Hansi N, Easom NJW, Burton AR, Stegmann KA et al. ( 2017 ) . IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection . Journal of Experimental Medicine vol. 214 , ( 6 ) 1567 - 1580 .

Salpini R, Piermatteo L, Gill U, Battisti A, Stazi F, Giannella S, Serafini V, Perno CF et al. ( 2017 ) . Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0 . Medical Microbiology and Immunology vol. 206 , ( 4 ) 295 - 299 .

Gill US, Peppa D, Micco L, Singh HD, Le Bert N, Rivino L, Kunasegaran K, Tan D et al. ( 2017 ) . Effect of in-vivo hepatitis B viral load suppression after interferon exposure on natural killer and T-cell responsiveness . vol. 389 , Elsevier

Salpini R, Battisti A, Anastasiou O, Gill U, Colagrossi L, Bertoli A, Fabeni L, Fini V et al. ( 2017 ) . In HBeAg-negative chronic HBV infection, HBsAg levels profoundly differ among HBV-genotypes and can be affected by the extent of HBsAg variability: Can quantitative HBsAg truly reflect intra-hepatic HBV reservoir? . Digestive and Liver Disease . vol. 49 ,

Salpini R, Colagrossi L, Battisti A, Hansi N, Perno CF, Gill US, Kennedy PTF, Svicher V ( 2017 ) . Peripheral and intrahepatic virological phenotyping in HBeAg negative Chronic Hepatitis B to evaluate risk of disease progression and HCC in the “grey-zone” viral load cohort: Can grey-zone patients be candidate to treatment? . Digestive and Liver Disease . vol. 49 ,

Huang W-C, Easom NJ, Tang X-Z, Gill US, Singh H, Robertson F, Chang C, Trowsdale J et al. ( 2017 ) . T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System . The Journal of Immunology vol. 198 , ( 3 ) 1172 - 1182 .

Salpini R, Battisti A, Anastasiou O, Gill U, Colagrossi L, Bertoli A, Fabeni L, Fini V et al. ( 2017 ) . FRI-133 In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir? . Journal of Hepatology . vol. 66 ,

Gill US, Bert NL, Kunasegaran K, Khakpoor A, Hansi N, Tan D, Rivino L, Singh HD et al. ( 2017 ) . FRI-297 Transcriptome profiles of NK and T cells associated with immune control in chronic hepatitis B patients treated with pegylated interferon alpha-nucleos(t)ide analogue sequential therapy . Journal of Hepatology . vol. 66 ,

Gill US, Hansi NK, Le Bert N, Kunasegaran K, Tan D, Dolman GE, Payaniandy L, Tong W et al. ( 2017 ) . HBV-specific T cell immunity in inactive carrier patients is independent of Hepatitis B surface antigen load . HEPATOLOGY . vol. 66 , 787A - 788A .

Salimzadeh L, Bert NL, Gill US, Kennedy PT, Samuel D, Novikov N, Pflanz S, Frey CR et al. ( 2017 ) . PS-049 Modifications of virus-specific and total B cell populations by hepatitis B virus infection . Journal of Hepatology . vol. 66 , s28 - s29 .

Le Bert N, Rivino L, Gill US, Cheng Y, Kunasegaran K, Tan DZ, Becht E, Hansi NK et al. ( 2017 ) . SAT-152 PD-1+ CD8+ T cells as immunological biomarkers for the safe discontinuation of anti-viral therapy in chronic hepatitis B . Journal of Hepatology . vol. 66 ,

Svicher V, Salpini R, Colagrossi L, Battisti A, Piermatteo L, Hansi N, Perno CF, Gill US et al. ( 2017 ) . SAT-186 Peripheral and intrahepatic virological phenotyping in eAg negative chronic hepatitis B to evaluate risk of disease progression and hepatocellular carcinoma in the “grey-zone” viral load cohort . Journal of Hepatology . vol. 66 ,

Gill US, Le Bert N, Kunasegaran K, Khakpoor A, Hansi NK, Tan D, Rivino L, Singh HD et al. ( 2017 ) . Transcriptome profiles of NK and T cells regulating immune control in chronic hepatitis B, proximate to patients treated with Pegylated Interferon alpha-Nucleos(t)ide analogue (NA) sequential therapy compared to de novo NA therapy . HEPATOLOGY . vol. 66 , 70A - 70A .

Hansi N, Gill U, Kennedy P ( 2016 ) . Chronic Hepatitis B . Liver Disease in Clinical Practice , Springer Nature

Hansi N, Troke P, Gill, Agarwal K, Aldersley M, Al-Shamma S, Brown A, Cobbold J et al. ( 2016 ) . PTH-107 Chronic Hepatitis B Management The UK: A National Survey of Current Practice Following Nice Guidance . Gut . Conference: BSG 2016 vol. 65 ,

Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PTF ( 2016 ) . Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo . PLOS Pathogens vol. 12 , ( 8 )

Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, Hong MLW, Naik S et al. ( 2016 ) . HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant . Gastroenterology vol. 151 , ( 5 ) 986 - 998.e4 .

Schurich A, Pallett LJ, Jajbhay D, Wijngaarden J, Otano I, Gill US, Hansi N, Kennedy PT et al. ( 2016 ) . Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host . Cell Reports vol. 16 , ( 5 ) 1243 - 1252 .

Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, Christophides T, Pallett LJ, Peppa D et al. ( 2016 ) . CXCR6 marks a novel subset of T-betloEomeshi natural killer cells residing in human liver . Scientific Reports vol. 6 , ( 1 )

Vergis N, Khamri W, Gill US, Blackmore LJ, Shawcross DL, Ma Y, Antoniades CG, Thursz MR ( 2016 ) . Effect of prednisolone therapy on monocyte phenotype and function in alcoholic hepatitis . The Lancet . vol. 387 ,

Rivino L, Le Bert N, Gill U, Cheng Y, Kunasegaran K, Tan D, Koh S, Hansi N et al. ( 2016 ) . PS056 An Immunological Biomarker to Predict Hepatic Flares upon Nuc Therapy Discontinuation in Chronic Hepatitis B . Journal of Hepatology . vol. 64 , s164 - s165 .

Svicher V, Salpini R, Gill US, Colagrossi L, Hansi NK, Perno CF, Kennedy PT ( 2016 ) . Peripheral and intrahepatic virological phenotyping in eAg negative Chronic Hepatitis B underlines the limitations of current treatment thresholds in low to moderate viraemic patients . HEPATOLOGY . vol. 64 , 308A - 308A .

Rivino L, Van Den Berg M, Gill, Le Bert N, Koh S, Hansi N, Newell E, Foster G et al. ( 2015 ) . PTU-103 Characterisation of the immune profile in chronic hepatitis b patients following nucleos(t)ide discontinuation by cytof mass cytometry . Gut . Conference: Liver – Viral Hepatitis vol. 64 ,

Hansi N, Gill, Banerjee M, Naik S, Tong W, Foster G, Carey I, Kennedy P ( 2015 ) . PTU-106 Identifying true immune-tolerant disease in children and young adults with chb using quantified hepatitis b surface antigen levels . Gut . Conference: Liver – Viral Hepatitis vol. 64 ,

Hansi N, Gill, Banerjee M, Naik S, Tong W, Foster G, Carey I, Kennedy P ( 2015 ) . PTU-107 Defining the low-risk inactive carrier in chronic hepatitis b with qhbsag: do the same rules apply in children and young adults? . Gut . Conference: Liver – Viral Hepatitis vol. 64 ,

Gill, Peppa D, Micco L, Singh H, Foster G, Maini M, Kennedy P ( 2015 ) . PTU-116 Functional immune restoration correlates with HBSAG decline and may predict treatment response on sequential NUC therapy in CHB . Gut . Conference: Liver – Viral Hepatitis vol. 64 ,

Gill, Hansi N, Payaniandy L, Schulz J, Payaniandy D, Alazawi W, Dearden J, Kallis Y et al. ( 2015 ) . PTU-117 Sequential NUC therapy following pegylated interferon provides a greater decline in HBSAG and potentially offers a treatment advantage over current therapies . Gut . Conference: Liver – Viral Hepatitis vol. 64 ,

Pallett LJ, Gill US, Quaglia A, Sinclair LV, Jover-Cobos M, Schurich A, Singh KP, Thomas N et al. ( 2015 ) . Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells . Nature Medicine vol. 21 , ( 6 ) 591 - 600 .

Gill US, Kennedy PT ( 2015 ) . New insights in the management of chronic hepatitis B . Clinical Medicine vol. 15 , ( 2 ) 191 - 196 .

Rivino L, Van Den Berg M, Le Bert N, Koh S, Gill US, Hansi NK, Foster GR, Bertoletti A et al. ( 2015 ) . P0474 : Characterisation of the immune profiles of chronic hepatitis B patients following NUC discontinuation by cyTOF mass cytometry . Journal of Hepatology . vol. 62 ,

Huang W-C, Peppa D, Easom N, Tang X-Z, Singh H, Fusai G, Rosenberg W, Ghosh I et al. ( 2015 ) . P0478 : NKG2D-dependent cross-talk between NK cells and CD4 T cells in chronic hepatitis B . Journal of Hepatology . vol. 62 ,

Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PT ( 2015 ) . P0485 : Functional immune restoration correlates with HBsAg decline and may predict treatment response on sequential NUC therapy in chronic hepatitis B . Journal of Hepatology . vol. 62 ,

Gill US, Rivino L, Le Bert N, Kunasegaran K, Tan D, Koh S, Van den Berg M, Cheng Y et al. ( 2015 ) . Characterisation of the immune profile in Chronic Hepatitis B, with CyTOF, to identify biomarkers of immune control following NUC therapy discontinuation . HEPATOLOGY . vol. 62 , 294A - 294A .

Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PT ( 2015 ) . NK cell function is restored with sequential NUC therapy and correlates with treatment response in Chronic Hepatitis B . HEPATOLOGY . vol. 62 , 1001A - 1002A .

Hansi NK, Seipt CC, Gill US, Naik S, Tong W, Foster GR, Carey I, Kennedy PT ( 2015 ) . Quantitative Hepatitis B surface antigen (qHBsAg) may define low-risk inactive carriers of CHB: Can this provide a framework for better management across all age-groups? . HEPATOLOGY . vol. 62 , 976A - 977A .

Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJW, Barr DA, Kallis YN, Marley RTC et al. ( 2014 ) . Assessment of Bone Mineral Density in Tenofovir-Treated Patients With Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk? . Journal of Infectious Diseases vol. 211 , ( 3 ) 374 - 382 .

Gill US, Kennedy PT ( 2014 ) . Chronic hepatitis B virus in young adults: the need for new approaches to management . Expert Review of Anti-infective Therapy vol. 12 , ( 9 ) 1045 - 1053 .

Jo J, Tan AT, Ussher JE, Sandalova E, Tang X-Z, Tan-Garcia A, To N, Hong M et al. ( 2014 ) . Toll-Like Receptor 8 Agonist and Bacteria Trigger Potent Activation of Innate Immune Cells in Human Liver . PLOS Pathogens vol. 10 , ( 6 )

Gill US, Peppa D, Micco L, Singh HD, Foster G, Maini M, Kennedy PT ( 2014 ) . Sa1313 Sequential Nuc Therapy Following Pegylated Interferon-Alpha Exposure Restores Innate Immune Responses Conferring a Treatment Advantage Over Nuc Monotherapy in Chronic Hepatitis B . Gastroenterology vol. 146 , ( 5 ) s - 260 .

Kennedy PTF, Gill US, Bertoletti A, Mason WS ( 2014 ) . O106 CLONAL HEPATOCYTE REPOPULATION IN THE YOUNG ADULT HBV INFECTED LIVER CHALLENGES THE CONCEPT OF A GENERIC IMMUNE TOLERANT DISEASE PHASE . Journal of Hepatology . vol. 60 ,

Pallett LJ, Haniffa M, Schurich A, Gill U, Davies N, Jover-Cobos M, Das A, Gilson R et al. ( 2014 ) . P132 MYELOID-DERIVED SUPPRESSOR CELLS MEDIATE IMMUNOTOLERANCE IN CHRONIC HEPATITIS B (CHB) THROUGH ARGININE DEPRIVATION . Journal of Hepatology . vol. 60 ,

Huang W-C, Peppa D, Easom N, Tan X-Z, Chang C, Trowsdale J, Gill U, Kennedy P et al. ( 2014 ) . P137 THE EXPRESSION OF NKG2D-LIGANDS BY ACTIVATED CD4 T CELLS RENDERS THEM SUSCEPTIBLE TO NK CELL REGULATION IN CHRONIC HEPATITIS B (CHB) . Journal of Hepatology . vol. 60 ,

Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PTF ( 2014 ) . P152 SEQUENTIAL NUC THERAPY FOLLOWING PEGYLATED INTERFERON-ALPHA EXPOSURE RESTORES INNATE IMMUNE RESPONSES CONFERRING A TREATMENT ADVANTAGE OVER NUC MONOTHERAPY IN CHRONIC HEPATITIS B . Journal of Hepatology . vol. 60 ,

Lubowiecki M, Pallmer K, Jajbhay D, Pallett LJ, Gill U, Kennedy PT, Maini M, Schurich A ( 2014 ) . P159 CO-INHIBITORY RECEPTOR LAG-3 POSITIVE CD8 T CELLS PRODUCE IMMUNOSUPPRESSIVE TGF-β IN CHRONIC HBV . Journal of Hepatology . vol. 60 , s118 - s119 .

Vergis N, Khamri W, Atkinson S, Tidswell R, Gill U, Ryan J, Bernsmeier C, Triantafyllou E et al. ( 2014 ) . P306 MONOCYTE OXIDATIVE BURST DEFECT PREDICTS RISK OF INFECTION IN ALCOHOLIC HEPATITIS . Journal of Hepatology . vol. 60 ,

Pallett L, Gill U, Jover-Cobos M, Schurich A, Singh K, Thomas N, Das A, Chen A et al. ( 2014 ) . Arginase-dependent metabolic regulation of hepatic immunopathology by myeloid-derived suppressor cells . IMMUNOLOGY vol. 143 , 154 - 154 .

Kennedy PT, Gill US, Chen A, Litwin S, Bertoletti A, Mason W ( 2014 ) . Clonal Hepatocyte expansion in the young adult HBV infected liver is at odds with the concept of a generic immune tolerant disease phase: can additional clinical parameters distinguish disease phase? . HEPATOLOGY . vol. 60 , 1032A - 1033A .

Gill US, Peppa D, Singh HD, Micco L, Foster GR, Maini MK, Kennedy PT ( 2014 ) . Functional innate immune responses are restored with sequential NUC therapy following Pegylated Interferon-Alpha exposure and not with NUC monotherapy in Chronic Hepatitis B . HEPATOLOGY . vol. 60 , 1020A - 1021A .

Hansi NK, Gill US, Banerjee A, Surendraraj N, Patel C, Naik S, Foster GR, Kennedy PT ( 2014 ) . High levels of Hepatitis B surface antigen (HBsAg) can exclude significant fibrosis and distinguishes true 'immune-tolerance' in children and young adults with Chronic Hepatitis B . HEPATOLOGY . vol. 60 , 985A - 986A .

Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S et al. ( 2013 ) . The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells . PLOS Pathogens vol. 9 , ( 3 )

Lubowiecki M, Pallmer K, Jajbhay D, Pallett LJ, Gill U, Kennedy PT, Maini MK, Schurich A ( 2013 ) . Co-inhibitory receptor LAG-3 positive CD8 T cells produce immunosuppressive TGF-β in chronic HBV . IMMUNOLOGY . vol. 140 , 145 - 145 .

Gill US, Patel C, Naik S, Dearden J, Kallis YN, Kooner P, Marley R, Aleong J-AC et al. ( 2013 ) . Collagen proportionate area but not Ishak fibrosis stage on liver biopsy correlates with age in Chronic Hepatitis B infected young adults . HEPATOLOGY . vol. 58 , 427A - 428A .

Chen A, Gill US, Ikin CR, Aleong J-AC, Foster GR, Kennedy PT ( 2013 ) . Differential Hepatitis B virus core nuclear/cytoplasmic staining is a marker of longevity of chronic infection but not disease phase . HEPATOLOGY . vol. 58 , 423A - 424A .

Pallett LJ, Haniffa M, Jover-Cobos M, Schurich A, Das A, Gill U, Davies N, Ghosh I et al. ( 2013 ) . Expansion of arginase-expressing myeloid-derived suppressor cells in hepatotropic viral infections . IMMUNOLOGY . vol. 140 , 97 - 97 .

Gill US, Zissimopoulos A, Al-shamma S, Burke K, McPhail M, Barr D, Ross V, Kallis Y et al. ( 2013 ) . FRAX SCORE IN THE ASSESSMENT OF BONE MINERAL DENSITY CHANGES IN TENOFOVIR TREATED CHRONIC HEPATITIS B PATIENTS . GUT . vol. 62 , A190 - A190 .

Gill US, Payaniandy L, Payaniandy D, Schulz J, Ross VA, Kallis YN, Kooner P, Marley RTC et al. ( 2013 ) . INDUCTION MAINTENANCE THERAPY IN CHRONIC HEPATITIS B; STEP-DOWN FROM COMBINATION LAMIVUDINE AND TENOFOVIR TO LAMIVUDINE MONOTHERAPY - A POTENTIAL NEW TREATMENT STRATEGY . JOURNAL OF HEPATOLOGY . vol. 58 , S302 - S302 .

Chen A, Schurich A, Aleong J-AC, Trivedi K, Gill U, Peppa D, Kennedy P, Bertoletti A et al. ( 2013 ) . PROBING HEPATIC ANTIGEN PRESENTATION IN PATIENTS WITH CHRONIC HBV INFECTION . JOURNAL OF HEPATOLOGY . vol. 58 , S136 - S136 .

Gill US, Payaniandy L, Schulz J, Payaniandy D, Ross V, Kallis Y, Kooner P, Marley R et al. ( 2013 ) . SEQUENTIAL ORAL ANTI-VIRAL THERAPY FOLLOWING PEGYLATED-INTERFERON-ALPHA FAILURE SIGNIFICANTLY INCREASES HBSAG DECLINE . GUT . vol. 62 , A189 - A190 .

Gill US, Peppa D, Micco L, Foster GR, Maini MK, Kennedy PT ( 2013 ) . Sustained restoration of innate immune responses and sAg decline in sequential NUC therapy following failed Pegylated-Interferon-α therapy in Chronic Hepatitis B . HEPATOLOGY . vol. 58 , 416A - 417A .

Peppa D, Gill US, Reynolds G, Easom NJW, Pallett LJ, Schurich A, Micco L, Nebbia G et al. ( 2012 ) . Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion . Journal of Experimental Medicine vol. 210 , ( 1 ) 99 - 114 .

Kennedy PTF, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, Naik S, Foster GR et al. ( 2012 ) . Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B . Gastroenterology vol. 143 , ( 3 ) 637 - 645 .

Gill U, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster G, Maini M et al. ( 2012 ) . Mo1837 Maximal Boosting of Innate Immunity During Pegylated Interferon-Aplha Therapy is Reached at 48 Weeks in E-Antigen Positive Chronic Hepatitis B . Gastroenterology vol. 142 , ( 5 ) s - 696 .

Patel C, Gill U, Alazawi W, Shaw P, Alstead EM, Kallis Y, Kooner P, Marley R et al. ( 2012 ) . Benchmarking disease activity and progression in Chronic Hepatitis B infected young adults . HEPATOLOGY . vol. 56 , 362A - 362A .

Gill US, Payaniandy L, Schulz J, Ross V, Kallis Y, Kooner P, Marley R, Ushiro-Lumb I et al. ( 2012 ) . CAN A 3-MONTH "STOPPING RULE" FOR PEGYLATED-INTERFERON-α BE APPLIED TO A UK POPULATION OF CHRONIC HEPATITIS B INFECTED PATIENTS OF MIXED GENOTYPE? . GUT vol. 61 , A145 - A145 .

Patel C, Gill US, Alazawi W, Shaw P, Alstead E, Kallis Y, Kooner P, Marley R et al. ( 2012 ) . EVALUATION OF LIVER FIBROSIS IN YOUNG ADULT PATIENTS WITH CHRONIC HEPATITIS B VIRUS . GUT vol. 61 , A133 - A133 .

Gill U, Zissimopoulos A, Al-Shamma S, Burke KB, Ross VA, Kallis Y, Kooner P, Marley R et al. ( 2012 ) . FRAX score in the assessment of Bone Mineral Density changes in Tenofovir treated Chronic Hepatitis B patients: comparison with bone biochemistry and DEXA scanning . HEPATOLOGY . vol. 56 , 201A - 201A .

Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, Chen A, Blair P et al. ( 2012 ) . IL-10-Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection . JOURNAL OF IMMUNOLOGY vol. 189 , ( 8 ) 3925 - 3935 .

Gill US, Payaniandy L, Payaniandy D, Schulz J, Ross V, Kallis Y, Kooner P, Marley R et al. ( 2012 ) . INDUCTION MAINTENANCE TREATMENT IN CHRONIC HEPATITIS B; STEP-DOWN FROM TENOFOVIR AND LAMIVUDINE TO LAMIVUDINE MONOTHERAPY IS EFFECTIVE . GUT vol. 61 , A145 - A145 .

Gill US, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster GR, Maini MK et al. ( 2012 ) . MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-APLHA THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B . JOURNAL OF HEPATOLOGY . vol. 56 , S175 - S175 .

Gill US, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster GR, Maini MK et al. ( 2012 ) . MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-α THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B . GUT vol. 61 , A145 - A146 .

Gill U, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster G, Maini M et al. ( 2012 ) . Maximal Boosting of Innate Immunity During Pegylated Interferon-Aplha Therapy is Reached at 48 Weeks in E-Antigen Positive Chronic Hepatitis B . GASTROENTEROLOGY . vol. 142 , S696 - S696 .

Gill U, Al-Shamma S, Burke KB, Ross VA, Marley R, Kooner P, Foster GR, Kennedy PT ( 2011 ) . BONE MINERAL DENSITY LOSS IN TENOFOVIR TREATED CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IS A CONSEQUENCE OF VITAMIN D DEFICIENCY AND NOT TENOFOVIR THERAPY . HEPATOLOGY . vol. 54 , 1012A - 1012A .

Kennedy PT, Sandalova E, Jo J, Gill U, Li L, Ushiro-Lumb I, Naik S, Foster GR et al. ( 2011 ) . IMMUNOLOGICAL ANALYSIS AND CLINICAL PROFILE OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN THE YOUNGER PATIENT . HEPATOLOGY . vol. 54 , 1092A - 1093A .

Gill US, Al-shamma S, Burke K, Ross V, Marley RTC, Kooner P, Foster GR, Kennedy PTF ( 2011 ) . P61 Bone mineral density loss in tenofovir treated Chronic Hepatitis B Virus (HBV) patients is a consequence of Vitamin D deficiency and not Tenofovir therapy . Gut vol. 60 , ( Suppl 2 )

Kennedy PTF, Sandalova E, Jo J, Gill US, Li L, Ushiro-Lumb I, Naik S, Foster GR et al. ( 2011 ) . P62 Immunological analysis and clinical profile of Chronic Hepatitis B Virus (HBV) infection in the younger patient . Gut vol. 60 , ( Suppl 2 )

Patel C, Gill U, Glyn FJ, Naik S, Foster G, Kennedy PT ( 2011 ) . Chronic HBV Infection: Assessment and Management of Disease in a Young Adult Clinic . Gastroenterology vol. 140 , ( 5 ) s - 454 .

Glyn FJ, Gill U, Alazawi W, Ross V, Kooner P, Marley R, Foster G, Kennedy PT ( 2011 ) . Efficacy of Combination Tenofovir Plus Lamivudine Versus Tenofovir Monotherapy in Patients With Chronic Hepatitis B Virus . Gastroenterology vol. 140 , ( 5 ) s - 455 .

Gunawan AS, Gill U, Glyn FJ, Kooner P, Marley R, Ushiro-Lumb I, Foster G, Kennedy PT ( 2011 ) . Utility of HBsAg Quantification in Developing an Individualised Approach to the Management of Chronic Hepatitis B Virus in Clinical Practice . Gastroenterology vol. 140 , ( 5 ) s - 458 .

Patel C, Gill US, Glyn F, Naik S, Foster GR, Kennedy PTF ( 2011 ) . CHRONIC HBV INFECTION: ASSESSMENT AND MANAGEMENT OF DISEASE IN A YOUNG ADULT CLINIC . GUT . vol. 60 ,

Glyn F, Gill US, Alazawi W, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF ( 2011 ) . EFFICACY OF COMBINATION TENOFOVIR PLUS LAMIVUDINE VERSUS TENOFOVIR MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS . GUT . vol. 60 , A231 - A231 .

Gill US, Al-Shamma S, Burke K, Ross V, Marley R, Kooner P, Foster GR, Kennedy PTF ( 2011 ) . FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT? . GUT . vol. 60 ,

Gill U, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster GR, Maini MK, Kennedy PTF ( 2011 ) . PEGYLATED INTERFERON A MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION . GUT . vol. 60 , A232 - A232 .

Gunawan A, Gill US, Glyn F, Kooner P, Marley R, Ushiro-Lumb I, Foster GR, Kennedy PTF ( 2011 ) . UTILITY OF HBSAG QUANTIFICATION IN DEVELOPING AN INDIVIDUALISED APPROACH TO THE MANAGEMENT OF CHRONIC HEPATITIS B VIRUS IN CLINICAL PRACTICE . GUT . vol. 60 ,

Glyn FJ, Gill U, Alazawi W, Ross V, Kooner P, Marley R, Foster G, Kennedy PT ( 2011 ) . Efficacy of Combination Tenofovir Plus Lamivudine Versus Tenofovir Monotherapy in Patients With Chronic Hepatitis B Virus . GASTROENTEROLOGY . vol. 140 , S455 - S455 .

Gill US, Al-Shamma S, Burke K, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF ( 2011 ) . FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT? . JOURNAL OF HEPATOLOGY . vol. 54 , S286 - S286 .

Gill US, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster GR, Maini MK, Kennedy PTF ( 2011 ) . PEGYLATED INTERFERON ALPHA MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION . JOURNAL OF HEPATOLOGY . vol. 54 , S32 - S32 .

Peppa D, Gill U, Micco L, Schurich A, Nebbia G, Singh H, Rosenberg W, Gilson R et al. ( 2011 ) . Susceptibility of T cells to death ligand-mediated deletion in the liver of chronic hepatitis B virus (CHB) infected patients . IMMUNOLOGY . vol. 135 , 60 - 60 .

Gunawan AS, Gill U, Glyn FJ, Kooner P, Marley R, Ushiro-Lumb I, Foster G, Kennedy PT ( 2011 ) . Utility of HBsAg Quantification in Developing an Individualised Approach to the Management of Chronic Hepatitis B Virus in Clinical Practice . GASTROENTEROLOGY . vol. 140 , S458 - S458 .

Foo FJ, Gill U, Verbeke CS, Guthrie JA, Menon KV ( 2007 ) . Ampullary carcinoma associated with an annular pancreas . JOP Journal of the Pancreas vol. 8 , ( 1 ) 50 - 54 .

Constantinides M, Gafton J, Garcia ACA, Genes and Health, Dixon PH, Williamson C, Linton K, Finer S et al. . A Genes & Health pilot recall study of intrahepatic cholestasis of pregnancy and cholestatic liver disease .

Fink D, Etoori D, Hill R, Idilli O, Kartikapallil N, Payne O, Griffith S, Bradford H et al. . Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFN non-response .

Gnanapavan S, Aboulwafa M, Ammoscato F, Andrews M, Alampritis G, Asardag AN, Baker D, Chance R et al. . COVID-19 exposure risks and protective measures in East London’s healthcare and academic sectors: Insights and applications of GloBody technology for infectious disease monitoring .

Huat NKK, Lim JME, Gill US, de Alwis R, Tan N, Toh JZN, Abbott JE, Usai C et al. . Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients .

Li W, Wang N, Kumar R, Mir IG, Gill U, Hood G, Brindley J, Mein C et al. . TLR5 drives metabolic dysfunction-associated steatohepatitis through lipid- and flagellin-induced hepatocyte injury signalling .

Wiggins BG, Pallett LJ, Li X, Davies SP, Amin OE, Gill US, Patel AM, Aliazis K et al. . The human liver microenvironment shapes the homing and function of CD4+T-cell populations .

Usai C, Gibbons JM, Pade C, Li W, Jacobs SRM, McKnight Á, Kennedy PTF, Gill US . The β-NGF/TrkA signalling pathway is associated with the production of anti- nucleoprotein IgG in convalescent COVID-19 .